Clinical trials: sponsored by Chinese PLA General Hospital
Metastatic Colorectal Cancer
Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
Molecular subtypes make difference on clinicopathologic features and response to chemotherapy and targeted agents as well as prognosis.
- Trial name
- NCT05522738
- Testing
- Combination: Fruquintinib + FOLFIRI
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Chinese PLA General Hospital
Malignant Solid Tumors
First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
This is the first-in-human study of 68Ga/64Cu-FAPI-XT117, which is an prospective, single-arm phase I clinical study.
- Trial name
- NCT05814835
- Testing
- 2-4 mCi 68Ga/64Cu-FAPI-XT117, 4-6 mCi 68Ga/64Cu-FAPI-XT117, 6-8 mCi 68Ga/64Cu-FAPI-XT117
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Chinese PLA General Hospital
Solid Tumor, Hematologic Malignancy
GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor
Immune checkpoint blockade has made great but unsatisfied success in treating cancers. One important reason is the hijacked HLA (Human Leukocyte Antigen) antigen presentation.
- Trial name
- NCT04944888
- Testing
- Eliglustat, Immune checkpoint inhibitor
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Chinese PLA General Hospital
Stroke, Acute
Early Neurological Trajectory and Clinical Outcomes in Brain Acute Ischemic Stroke
Prospective identification of potential responsible blood vessels, provision of intervention targets, prevention of fatal and disabling cerebrovascular diseases, identification of early END patients, determination of clinical…
- Trial name
- NCT06170086
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
HER2 Positive Advanced Solid Tumors
HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors
Chimeric antigen receptor modified T (CAR-T) cell therapy still has multiple difficulties in solid tumors, such as absence of tumor specific antigens, complex immunosuppressive tumor microenvironment, and tumor heterogeneity.
- Trial name
- NCT05681650
- Testing
- HypoSti.CAR-HER2 T cells, Albumin-bound paclitaxel, Cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Solid Tumor, Lymphoma
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas
The potency of immune checkpoint blockade is limited in most solid malignancies, one possible reason for which is tumor microenvironment.
- Trial name
- NCT04407741
- Testing
- SHR2554+SHR1701, SHR1701
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
aGVHD, Stem Cell Transplant Complications
First Line Therapy for High Risk Acute GVHD
The purpose of this study is to determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for the Treatment of High risk aGVHD(acute graft-versus-host disease )
- Trial name
- NCT04061876
- Testing
- Ruxolitinib, Corticosteroid
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Chinese PLA General Hospital
EBV-associated Hemophagocytic Lymphohistiocytosis, EBV Infection
Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection
This is a multi-center, single arm, open-label, phase I study to determine the safety and effectiveness of EBV-TCR-T cell immunotherapy in treating EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) or EBV infection
- Trial name
- NCT06135922
- Testing
- EBV-TCR-T cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Chinese PLA General Hospital
Stroke Sequelae, Deep Brain Stimulation
Safety and Efficacy Study of Implantable Neuromodulation for Poststroke Hemiplegia
Background: Hemiplegia is a common complication after a stroke. Studies have shown that traditional medical and rehabilitation treatments are not good for improving patients' motor function, deep brain stimulation (DBS) and vagus…
- Conditions
- Stroke Sequelae, Deep Brain Stimulation, Vagus Nerve Stimulation, Motor Recovery
- Trial name
- NCT06121947
- Testing
- The DBS electrodes are implanted into MLR., The electrodes are implanted into the patient's vagus nerve
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Chinese PLA General Hospital
Heart Block, Risk Factor
New-onset Heart Blocks After Noncardiac Surgery: a Retrospective Study of More Than 280,000 Patients
This study aimed to investigate new-onset heart blocks after noncardiac surgery, identify risk factors, and develop a prediction model.
- Trial name
- NCT06119009
- Testing
- non interventions
- Volunteers
- 281,497 people
- Sponsor
- Chinese PLA General Hospital
Gastric Cancer
Use of a Liquid Biopsy Signature to Detect Early-onset Gastric Cancer
Early-onset gastric cancer (EOGC) is a lethal malignancy with a poor prognosis. It differs from late-onset gastric cancer (LOGC) in clinical and molecular characteristics.
- Trial name
- NCT06023121
- Testing
- Measurement of levels of an exosome-based liquid biopsy signature
- Where
- China
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Neoplasms, Liver, Neoplasms Malignant
Clinical Application of Super-resolution Ultrasound(SR-US) Imaging in Solid Tumors
It has well accepted that tumor angiogenesis present aberrant vascular architecture and functional abnormalities, which is associated with tumorigenesis, tumor propagation and progression.
- Conditions
- Neoplasms, Liver, Neoplasms Malignant, Neoplasm Metastasis, Ultrasound
- Trial name
- NCT06018142
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Solid Tumor, Adult, Lymphoma
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
This is a pilot clinical trial for subjects with local advanced/metastatic solid tumors or relapsed/refractory (R/R) lymphomas to determine the safety, efficacy and immune response of autologous EphA2-targeting CAR-DC vaccine…
- Conditions
- Solid Tumor, Adult, Lymphoma, EphA2 Overexpression, TP53 R273H
- Trial name
- NCT05631886
- Testing
- TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Chinese PLA General Hospital
Hearing Loss, Pendred Syndrome
Clinical Phenotypic Characteristics of SC26A4
The presence or absence of SC26A4, whether combined with Mondini malformation, and patient age, are important factors affecting the degree of hearing loss in the Chinese population.
- Trial name
- NCT05970445
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Chinese PLA General Hospital
Stroke Sequelae
Efficacy and Safety of Deep Brain Stimulation in Mesencephalic Locomotor Region（MLR） for Poststroke Hemiplegia
Abstract: Background: The leftover movement disorder of stroke patients is one of the main causes of disability, and there is still no specific solution.
- Trial name
- NCT05968248
- Testing
- MLR-DBS, Conventional rehabilitation group
- Volunteers
- 62 people
- Sponsor
- Chinese PLA General Hospital
Cervical Dystonia
Comparison of Pallidal With Subthalamic Deep Brain Stimulation for Cervical Dystonia
Cervical dystonia (CD), also known as spasmodic torticollis, is a type of focal dystonia, mainly manifesting as involuntary head turning or tilting, or holding a twisted posture.
- Trial name
- NCT05715138
- Testing
- GPi-DBS, STN-DBS, GPi-DBS devices
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Chinese PLA General Hospital
Solid Tumor, Adult
CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors
In this single-center, single-arm,prospective, open-label, phase 1/2 study, the safety and efficacy of autologous CD70 targeted chimeric antigen receptor modified T (CAR-T) cell therapy will be evaluated in patients with CD70…
- Trial name
- NCT05947487
- Testing
- CD70-targeting CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Lymphoma
CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma
In this single-center, single-arm,prospective, open-label, phase 1/2 study, the safety and efficacy of autologous CD70 targeted chimeric antigen receptor modified T (CAR-T) cell therapy will be evaluated in patients with CD70…
- Trial name
- NCT05948033
- Testing
- CD70-targeting CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
COVID-19, Renal Insufficiency, Chronic
Efficiency and Safety of Paxlovid for COVID-19 Patients With Severe Chronic Kidney Disease
This is a prospective, single-center, open and self-controlled study.The purpose of this study is to evaluate the efficacy and safety of Paxlovid for the treatment of COVID-19 patients with severe chronic kidney disease.
- Trial name
- ESPTCSCKD (NCT05938140)
- Testing
- Nirmatrelvir/ritonavir
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Non-hodgkin Lymphoma,B Cell
TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL
The team has developed a chimeric antigen receptor (CAR) based on T cell receptor (TCR) complex, called synthetic TCR and antigen receptor (STAR).
- Trial name
- NCT05631912
- Testing
- Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide
- Where
- 2 sites in China
- Volunteers
- 38 people
- Sponsor
- Chinese PLA General Hospital